SynektikFRA:A2P +4.17%60 PB Ratio is 19.45 as of Jul. 04, 2026, which is 648% above its 10-year median of 2.60. GuruFocus rates FRA:A2P with a GF Score™ of 60/100 and a GF Value™ of €52.48 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Synektik ranks worse than 96.57% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-04), Synektik's share price is €83.70. Synektik's Book Value per Share for the quarter that ended in Mar. 2026 was €4.30. Hence, Synektik's PB Ratio of today is 19.45.
Warning Sign:
Synektik SA stock PB Ratio (=19.43) is close to 10-year high of 19.43.
The historical rank and industry rank for Synektik's PB Ratio or its related term are showing as below:
FRA:A2P'
s PB Ratio Range Over the Past 10 Years
Min: 0.85 Med: 2.6 Max: 19.43
Current: 19.43
During the past 13 years, Synektik's highest PB Ratio was 19.43. The lowest was 0.85. And the median was 2.60.
FRA:A2P's PB Ratio is ranked worse than 96.57% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs FRA:A2P: 19.43
During the past 12 months, Synektik's average Book Value Per Share Growth Rate was -5.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 33.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.30% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 10.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Synektik was 153.30% per year. The lowest was -6.50% per year. And the median was 10.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Synektik PB Ratio Related Terms
Synektik PB Ratio Historical Data
* Premium members only.
The historical data trend for Synektik's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Synektik's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Synektik PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Synektik's PB Ratio distribution charts can be found below:
* The bar in red indicates where Synektik's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Synektik's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Synektik (FRA:A2P) has a PB Ratio of 19.45 as of Jul. 04, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Synektik and its competitors. This is 648% above median its historical median of 2.60. Over the past decade, Synektik's PB Ratio has ranged from 0.85 to 19.43. According to the industry distribution chart, Synektik ranks #760 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 96.6%.
Is Synektik's PB Ratio too high?
Synektik's current PB Ratio of 19.45 is 648% above median its 10-year median of 2.60. Over the past 10 years, this metric has ranged from a low of 0.85 to a high of 19.43. The Medical Devices & Instruments industry median PB Ratio is 2.09. Synektik's value of 19.45 is 830.6% above this industry median. Based on the distribution chart, Synektik ranks #760 out of 787 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Synektik has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Synektik's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Synektik ranks #760 out of 787 companies for PB Ratio. This places Synektik in the lower half of its industry. The industry median PB Ratio is 2.09. Synektik's value of 19.45 is 830.6% above this benchmark. Historically, Synektik's own PB Ratio has ranged from 0.85 to 19.43 over the past decade. While the company's 10-year median is 2.60 vs. the industry median of 2.09, Synektik has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.09, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Synektik's current PB Ratio of 19.45 is 830.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Synektik and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Synektik's current PB Ratio is 19.45, which is 648% above median its own 10-year median of 2.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Synektik stock overvalued right now?
Based on GuruFocus' analysis, Synektik (FRA:A2P) is currently considered Significantly Overvalued. The stock's GF Value™ is €52.48, compared to a current price of €83.70 — trading 59.5% above its estimated fair value. The current PB Ratio is 19.45, which is 648% above median its 10-year median of 2.60 and 830.6% above the Medical Devices & Instruments industry median of 2.09. Synektik's overall GF Score™ is 60/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Synektik (FRA:A2P), the current PB Ratio is 19.45 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Synektik (FRA:A2P) Overvalued in 2026?
Based on GuruFocus' analysis, Synektik stock appears to be overvalued.
The current stock price of €83.70 is trading 59.5% above its estimated GF Value™ of €52.48.
GuruFocus considers Synektik to be Significantly Overvalued.
Key valuation signals for FRA:A2P:
PB Ratio: 19.45 (648% above median its 10-year median of 2.60)
GF Value™: €52.48 vs. price of €83.70 (59.5% above fair value)
Industry Position: 830.6% above the Medical Devices & Instruments median (#760 of 787)
No single metric tells the full story. See the FRA:A2P stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Synektik SA is a supplier of innovative products, services and IT solutions for diagnostic imaging and nuclear medicine. It sells medical devices and IT solutions used in radiology and operates research laboratory for diagnostic imaging systems and a service centre for medical equipment. Its operating segments include the sale of medical equipment used in radiology and nuclear medicine and IT solutions, Maintenance services for medical equipment as well as acceptance and specialist tests and Radiopharmaceutical production.
60GF Score
Get the complete analysis for FRA:A2P
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:A2P has been successfully added to your 
